The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.
|Original language||English (US)|
|State||Published - 2022|
- bispecific T cell engagers
ASJC Scopus subject areas
- Immunology and Allergy